- In March 2024, Pfizer Inc. received marketing authorization from the European Commission for its 20-valent pneumococcal conjugate vaccine, PREVENAR 20. This vaccine is approved for active immunization in infants, children, and adolescents aged 6 weeks to under 18 years. The approval marks a significant step in expanding pneumococcal disease prevention in pediatric populations across Europe
- In February 2024, SK Bioscience, in collaboration with the International Vaccine Institute (IVI), announced that its typhoid conjugate vaccine (TCV) has been prequalified by the World Health Organization (WHO). This milestone enables the vaccine to be procured by UN agencies, significantly boosting its availability in global markets. The prequalification is a key step in increasing the worldwide supply and distribution of TCV, contributing to enhanced public health efforts against typhoid
- In August 2022, Nigeria announced the introduction of Bharat Biotech's ROTAVAC® vaccine for the immunization of children, aimed at reducing the burden of infectious diseases. This initiative ensures that countries in Africa, such as Nigeria, have access to cost-effective, world-class vaccines for infants and vulnerable populations. ROTAVAC® has been proven safe and effective in preventing diarrheal diseases caused by Rotavirus, contributing to improved public health outcomes in the region
- In July 2023, the Serum Institute of India announced that its MenFive® vaccine, which protects against the leading causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive® targets meningococcal serogroups A, C, W, Y, and X and was developed through a 13-year collaboration between the Serum Institute and PATH, with substantial funding from the UK government’s Foreign, Commonwealth, and Development Office. This prequalification marks a significant milestone in improving public health and combating meningitis in Africa
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Monovalent Conjugate Vaccines, and Multivalent Conjugate Vaccines), Indication (Pneumococcal Disease, Influenza, Meningococcal Disease, and Others), End Users (Hospitals, homecare, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2032
.
The Global Conjugate Vaccines Market size was valued at USD 21.40 USD Billion in 2024.
The Global Conjugate Vaccines Market is projected to grow at a CAGR of 12.55% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
